Universitätsklinikum Tübingen

First clinical postmarketing experiences in the treatment of epilepsies with brivaracetam: A retrospective observational multicentre study (2019) Menzler K, Mross PM, Rosenow F, Schubert-Bast S, Willems LM, Zahnert F, Immisch I, et al. Journal article A phase I dose-escalation and expansion trial of intratumorally administered CV8102, alone and in combination with anti-PD-1 in patients with advanced solid tumours (2019) Krauss J, Eigentler T, Schreiber J, Weishaupt C, Terheyden P, Heinzerling L, Mohr P, et al. Conference contribution CLINICAL AND VIROLOGICAL CHARACTERISTICS AND RETREATMENT OF HCV-INFECTED PATIENTS WITH FAILURE TO MULTIPLE SUBSEQUENT DAA THERAPIES (2019) Dietz J, Vermehren J, Peiffer KH, Wietzke-Braun P, Muellhaupt B, Schattenberg J, Antoni C, et al. Conference contribution Does anti-acid treatment influence disease progression in SSc-ILD ? data from the German SSc-network (2019) Kreuter M, Bonella F, Blank N, Siegert E, Henes J, Worm M, Sunderkoetter C, et al. Conference contribution Long term outcomes of immunomodulatory drugs in SSc-ILD - data from the German SSc-network (2019) Kreuter M, Bonella F, Blank N, Siegert E, Henes J, Worm M, Sunderkoetter C, et al. Conference contribution Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis (2019) Becker M, Graf N, Sauter R, Allanore Y, Curram J, Denton CP, Khanna D, et al. Journal article Correction to: Curriculum for sports cardiology (Der Kardiologe, (2019), 13, 1, (26-37), 10.1007/s12181-019-0299-0) Erratum zu: Curriculum Sportkardiologie (Der Kardiologe, (2019), 13, 1, (26-37), 10.1007/s12181-019-0299-0) (2019) Burgstahler C, Pressler A, Berrisch-Rahmel S, Mellwig KP, Bongarth C, Halle M, Niebauer J, et al. Journal article, Erratum A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: Clinical results and biomarker analysis of GeparNuevo study (2019) Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, et al. Journal article Limited Effect of Anti-PD-1 in advanced Skin Tumors of Patients with hemato-oncological Primary Disease: A retrospective multi-center Study of ADO (2019) Leiter-Stoeppke U, Loquai C, Meier F, Rafei-Shamsabadi D, Hassel J, Glutsch V, Sirokay J, et al. Conference contribution Association of an initial Exanthem with Vemurafenib and Cobimetinib for a better Therapeutic Success in metastatic Melanoma Patients (2019) Kaehler K, Bohne AS, Gutzmer R, Satzger I, Meier F, Reinhardt L, Zimmer L, et al. Conference contribution